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Fragility fractures are recognized complication of diabetes, but yet the underlying mechanisms
remain poorly understood. This is particularly pronounced in type 2 diabetes in which the pro-
pensity to fall is increased but bone mass is not necessarily low. Thus, whether factors implicated
in thedevelopmentof insulin resistanceanddiabetesdirectly impactonthemusculoskeletal system
remains to be investigated. PPAR/ mice have reduced metabolic activity and are glucose in-
tolerant. We examined changes in bone and muscle in PPAR/mice and investigated both the
mechanism behind those changes with age as well as their response to exercise. Compared with
their wild type, PPAR/ mice had an accelerated and parallel decline in both muscle and bone
strengthwith age. These changeswere accompanied by increasedmyostatin expression, lowbone
formation, and increased resorption. In addition,mesenchymal cells from PPAR/had a reduced
proliferation capacity and appeared to differentiate into more of an adipogenic phenotype. Con-
comitantly we observed an increased expression of PPAR, characteristic of adipocytes. The ana-
bolic responses of muscle and bone to exercise were also diminished in PPAR/mice. The peri-
osteal bone formation response to direct bone compressionwas, however, maintained, indicating
that PPAR controls periosteal bone formation through muscle contraction and/or metabolism.
Taken together, these data indicate that PPAR deficiency leads to glucose intolerance, decreased
muscle function, and reduced bone strength. On a molecular level, PPAR appears to regulate myo-
statin and PPAR expression in muscle and bone, thereby providing potential new targets to reverse
bone fragility in patients with metabolic disturbances. (Endocrinology 155: 4686–4696, 2014)
Several cohort studies and meta-analyses have demon-strated that people suffering from type 2 diabetes mel-
litus (T2DM) have a higher risk of fracture despite their
higher-than-average bone mineral density (BMD) (1–3).
The surprisingly higher incidence of fracture in T2DM
may be explained by both a decrease in bone quality and
an increased propensity to fall. Recent investigations in
humans have indicated there is a negative alteration of the
trabecular and cortical microarchitecture as well as the
bone material properties, ie, components of bone quality,
in patients with T2DM (4, 5). There are several potential
mechanisms for reduced bone quality in diabetic patients,
including reduced bone formation, increased bone resorp-
tion, collagen modifications by advanced glycation end
products, and lipid accumulation in the bone marrow (6).
In addition, there are a number of mechanisms by which
diabetes may contribute to falls, including peripheral neu-
ropathy and decreased muscle strength (7, 8). Interest-
ingly, all T2DM features such as insulin resistance and
reduced muscle strength have been associated with low
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levels of physical activity (9), suggesting that exercise
training itself may be an efficient intervention in the man-
agement of T2DM. Several rodent models have been de-
veloped and/or are currently being investigated to help
elucidate the pathophysiology of bone fragility in diabe-
tes; however, most of these models have inherent limita-
tions so that the molecular mechanisms that may link
alterations in glucose and bone metabolism to muscle
and bone alterations remain unclear (10). In particular,
the molecular mechanisms for the potentially impaired
musculoskeletal response to exercise have not been
investigated.
Transcription factors of the peroxisome proliferator-
activated receptor (PPAR) family (PPAR, PPAR,
PPAR) are known to play an important role in energy
balance. PPAR and more recently PPAR have been
shown to be implicated in metabolic dysregulation. More
precisely, a decrease in PPAR expression results in de-
creased glycolysis and lipogenesis in the liver while in-
creasing fat infiltration in skeletal muscle (11–13). Thus,
PPAR/mice are metabolically less active and develop
glucose intolerance (11).Conversely, activationof PPAR
genetically or pharmacologically promotes muscle oxida-
tive capability by increasing the number of mitochondria
formed in the cell, up-regulating myoglobulin, and in-
creasing theproportionof type I (oxidative or slow twitch)
muscle fibers (15–17). Hence, sufficient PPAR expres-
sion positivelymodulates the capacity to performphysical
activity, improves insulin sensitivity, and leads to reduced
adiposity. It is not surprising therefore that a PPAR ag-
onist hasbeenused inananimalmodel to successfully treat
insulin resistance (18).
In addition to their lower muscle mass, reduced power,
and resistance (15, 16), PPAR/ mice have recently
been reported to have increased bone turnover and de-
creased bone mass (20). This observation implicates
PPAR in the pathogenesis of bone fragility observed in
diabetes. Thiswork showed that in the absence ofPPAR,
Wnt--catenin signaling was altered and associated with
lower osteoprotegerin, higher osteoclast number, and os-
teopenia. However, the function of PPAR on bone for-
mation, particularly bone modeling, and its role in the
bone response to exercise is yet to be elucidated. Here we
characterize alterations in the biomechanical responses of
bones from PPAR/ mice and identify new molecular
targets, namely PPAR and myostatin, that may contrib-
ute to the impairment of the muscle and bone functions in
diabetes.
Materials and Methods
Animals
PPAR/ mice were generated from a mixed background
(Sv129/C57BL/6) and have been previously described (21).Mice
were housed five per cage, maintained under standard nonbar-
rier conditions, and had access to water and soft diet ad libitum
(Harlan Teklad 2019, SDS). The mice were maintained at 22°C
with a12-hour light, 12-hour dark cycle. A first group of mice
was used to describe the role of PPAR on bone and muscle
phenotype in growing, young adult, adult, and old mice from 1
to 18 months old (n 8 female mice/group); a second group of
12-week-old male mice were used for the treadmill exercise (n
8malemice/group), and a supplemental groupofmalemice aged
14weekswere used for the axial compression studies (n6male
mice/group). Tomeasure the dynamic indices of bone formation,
mice received sc injections of calcein 9 and 2 days before
euthanasia.
The femurs, tibiae, and vertebrae were excised and cleared of
fat and connective tissues. Bone andmuscle tissue thatwere to be
used for RNA analysis were freshly extracted and frozen on
liquid nitrogen. Bones for histomorphometry analysis were im-
mediately fixed in 10% formaldehyde for 48 hours at 4°C.
Other bones were placed in damp cloth and frozen at20°C for
subsequent microarchitectural and biomechanical tests. All an-
imal procedureswere designed in accordancewith the Swiss Fed-
eral Act on Animal Protection, approved by the University of
Geneva School of Medicine Ethical Committee and the State of
Geneva Veterinarian Office.
Glucose tolerance tests
Glucose tolerance tests were performed after a 6-hour fast by
measuring blood glucose on glucose strips and an Accu-check
glucometer (Roche) at baseline and at 15, 30, 60, 90, and 120
minutes after an ip injection of glucose at 2 g/kg body weight.
Blood was obtained after an incision at the base of the tail.
Handgrip test and locomotor activity
In vivo hindlimb grip strength was measured using an auto-
mated grip strength (Bioseb; In Vivo Research Instruments) as
previously described (22). Eachmousewas tested five timeswith
a 40-second rest interval between tests. The average peak tension
and the best attempts were used as a gauge of muscle strength.
Two locomotor tests were performed using a treadmill to eval-
uate both endurance and aerobic maximum speed. For the eval-
uation of endurance, mice from each group were placed on the
treadmill, submitted tomoderate exercise at a speedof14m/min,
and were left to run for as long as they could (mice were con-
sidered fatiguedwhen they touched the back of the treadmill five
times). The collected end point data were the distance and the
time run by eachmouse. For the evaluation of aerobicmaximum
speed, exercise workloads were selected to gradually progress in
increments from moderate to maximal intensity. The exercise
beganwith 5minutes of exercise at a speedof 8m/min, and speed
was thereafter increased by 2 m/min every 2 minutes. The max-
imal speed was presented as the aerobic maximum speed.
Exercise training
Twelve-week-old male mice were randomly allocated into
sedentary and exercise-trained groups for each genotype:
PPAR/ and PPAR/ mice. The mice were trained 5 days
per week for 6weeks. The exercise protocol was determined and
adapted to the maximal capacity of PPAR/mice to perform
anexercise ona treadmill: at a speedof 16m/min, for 30minutes,
with an inclination of 5%.During the first acclimatizationweek,
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the treadmill speedand thedurationof each running sessionwere
gradually increased from8m/min for 10minutes to16m/min for
30 minutes. For the last 5 weeks, the running sessions consisted
of 16 m/min for 30 minutes with a treadmill inclination of 8°,
corresponding to moderate exercise at this specific age (16).
In vivo axial compression
Fourteen-week-old male mice were subjected to axial com-
pression stimulation on 3 alternate days per week for 2 weeks.
The loading apparatus used had been specifically adapted for
mice tibiae as previously described (23). Mice were anesthetized
by isoflurane 2%, and the tibiae were placed on the stimulation
machine between themoving padon the proximal side (the knee)
and the fixedpadon thedistal side (the foot).The left tibiaof each
mouse was subjected to dynamic axial stimulation, using the
following parameters: peak load 12 N; peak strain (midshaft
cortex)  1500 ; pulse period (trapeze shaped pulse)  0.1
second; rest time between pulses  10 seconds; and full cycle
frequency (pulse rest) 0.1 Hz. A total of 40 cycles (7 min)
were applied per session. The nonstimulated right tibia served as
an internal control.
In vivo measurement of body composition and
BMD
Body composition and total body, femoral, and spinal BMD
(grams per square centimeter) were measured in vivo by dual-
energy X-ray absorptiometry (PIXImus2; GE Lunar) at 12 and
18 weeks of age in the exercise experiment; at 13 and 16 weeks
of age in the axial compression experiment; and at 1, 4, 12, and
18 months for the aging experiment. Lean limb mass was eval-
uated by positioning the region of interest perpendicular to the
vertebral column and with the corner of the region of interest
aligned to the anterior margin of the hip.
Ex vivo measurement of morphology and
microarchitecture
Microcomputed tomography (UCT40; Scanco Medical AG)
was used to assess the trabecularmicroarchitecture in the excised
fifth lumber spine body and distal femur and cortical bone ge-
ometry at themidshaft femoral diaphysis as previously described
(24). Trabecular and cortical bone regions were evaluated using
an isotropic voxel resolution of 12 m. For the vertebral tra-
becular region, we evaluated 250 transverse computed tomog-
raphy slices between the cranial and caudal end plates, excluding
100mnear each endplate. For the femoral and tibial trabecular
regions, to eliminate the primary spongiosa, we analyzed 100
slices from the 50 slices under the distal growth plate. Femoral
cortical geometry was assessed using 50 continuous computed
tomography slides (600m) located at the femoralmidshaft. For
the trabecular bone regions, we assessed the bone volume frac-
tion (BV/TV, percentage), trabecular thickness (micrometers),
trabecular number (millimeters1), trabecular connectivity den-
sity (millimeters3), and structural model index. For the cortical
bone at the femoral and tibialmidshaft,wemeasured the cortical
tissue volume (CtTV; cubic millimeters), cortical bone volume
(CtBV; cubic millimeters), the marrow volume (cubic millime-
ters), and the average cortical width (micrometers). To evaluate
bone marrow adiposity tibias, we processed protocol with os-
mium staining as described (25). After labeling of lipids by os-
mium tetroxide, the bones were imaged using energy of 45 keV.
Testing of mechanical resistance
The night before the mechanical testing, bones were thawed
slowly at 7°Cand thenmaintainedat roomtemperature.A three-
point bending test was performed on the femur as follows: bones
were placed on the material testing machine on two supports
separated by a distance of 9.9 mm, and the load was applied to
the midpoint of the shaft. The mechanical resistance to failure
was tested using a servocontrolled electromechanical system (In-
stron 1114; Instron Corp) with the actuator displaced at 2 mm/
min. Outcomes measured were ultimate force, stiffness, and en-
ergy as described previously (26).
Histomorphometry
After 48 hours of fixation, boneswere dehydrated in absolute
acetone and embedded in methyl-methacrylate (Merck), and
8-m-thick transversal sections of the midshaft were cut with a
Leica Polycut E microtome (Leica Corp Microsystems AG) and
mounted unstained for the evaluation of fluorescence. Five-mi-
crometer-thick sagittal sections were stained with modified
Goldner’s trichrome, and histomorphometric measurements
wereperformedon the secondary spongiosaof theproximal tibia
metaphysis and on the endocortical and periosteal bone surfaces
in the middle of the tibia using a Leica Q image analyzer (Leica
Corp) at40magnification. All parameterswere calculated and
expressed according to standard formulas and nomenclatures
(27): mineral apposition rate (micrometers per day), mineraliz-
ing surface per bone surface (percentage), bone formation rate
(cubic micrometers per square micrometer per day). Osteoclast
surface per bone surface and numbers were evaluated only at 4
and 18 months of age.
RNA extraction and quantitative PCR
The whole tibia was excised, and both tibial extremities were
cut to remove the bone marrow from the diaphysis by flushing
with cold PBS. Muscle gastrocnemius was frozen by dipping
them on liquid nitrogen. Muscle and tibial diaphysis plus ex-
tremities were immediately pulverized to a fine powder and ho-
mogenized in peqGold Trifast (peQLab Biotechnologie GmbH)
using FastPrep system apparatus (QBiogene). Total RNA was
extracted and then purified on minicolumns (RNeasy minikit;
QIAGEN) in combination with a deoxyribonuclease treatment
(ribonuclease free deoxyribonuclease set; QIAGEN) to avoid
DNAcontamination. Single-strandedcDNAtemplates forquan-
titative real-time PCR analyses were carried out using Super-
Script III reverse transcriptase (Invitrogen AG) following the
manufacturer’s instructions. Quantitative RT-PCR was per-
formed using predesigned TaqMan gene expression assays (ref-
erences in Supplemental Material). Relative quantities were cal-
culatedwith the formula, relative quantityE cycle threshold
using an efficiency (E) of 2 by default. For each gene the mean
quantitywas calculated from triplicates for each sample, and this
quantity was normalized to the similarly measured mean quan-
tity of the glyceraldehyde-3-phosphate dehydrogenase normal-
ization gene. Finally, normalized quantities were averaged for
three to four animals.
Primary osteoblast culture
Primary osteoblast cultures were isolated from PPAR/
and PPAR/ newborn calvaria in a medium permissive to
mineralization. For this purpose, cells were harvested by sequen-
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tial collagenase type II (3 mg/mL; Sigma-Aldrich) digestions of
calvaria from 2- to 3-day-old PPAR/ or PPAR/ mice,
half issued frommale and half from female pups. Cells from the
third to fifth digestions were pooled and cultured in MEM
(Gibco), supplemented with 10% fetal calf serum (Amimed),
antibiotics (penicillin 100 U/ml, streptomycin 100 g/mL;
Gibco), glutamine (200 mM; Gibco), amino acids (Amimed),
and amphotericin B (0.25 g/mL; Amimed). Parameters mea-
sured included cell proliferation, differentiation, and relative
gene expression of osteoblast and osteocyticmarkers (details are
described in Supplemental Material).
Bone marrow mesenchymal stem cell enriched
culture
Mesenchymal stem cells (MSCs) were isolated from the fe-
murs ofPPAR/ andPPAR/ adultmice. For this purpose,
after removing soft tissue and epiphysis, bone marrow was
flushed with DMEMmedium.Marrow was then submitted to a
15-min enzymatic digestion. Collagenase activity was neutral-
ized and marrow was then resuspended in MEM (Gibco) sup-
plementedwith10%fetal calf serum(Amimed), antibiotics (pen-
icillin 100 U/mL, streptomycin 100 g/mL; Gibco), glutamine
(200 mM; Gibco), amino acids (Amimed), and amphotericin B
(0.25 g/mL; Amimed). The cells were plated at 106/cm3 cells in
a T75 flask and incubated at 37°Cwith 5%CO2, and the media
were changed every 3 days until the cells reached 80% conflu-
ence. Outcomeswere the quantification ofMSC PPAR/ and
PPAR/ differentiation into adipocyte and osteoblast popu-
lations. For adipogenesis, whenMSCs reached 100% of conflu-
ence, adipogenesicmedia (DMEMwith 10%fetal bovine serum,
1 m dexamethasone, 0.5 mm isobutylmethylxanthine, 10
g/mL insulin, and 100 m indomethacin) were added. After 3
days of the adipogenic medium, cells were returned to amedium
with DMEM, l0% fetal calf serum, l m dexamethasone, and 5
pg/mL insulin that was refreshed twice per week. After 14 days
in culture, adipocytes were visualized by oil red staining and
quantified at 540 nm on a spectrophotometer. For osteoblasto-
genesis,when theMSCs reached100%of confluence, osteogenic
media (DMEM with 10% fetal bovine serum, 10% 100 mM
-glycerophosphate, 108M dexamethasone, 5 mg ascorbic ac-
id-2 phosphate) were added and replaced twice per week. After
14 days in culture, calcium depositions were visualized by aliz-
arin red S staining and quantified at 405 nm on a
spectrophotometer.
Collection of serum
Blood from all mice was obtained by a submandibular col-
lection at 1 and 18 months of age. After centrifugation, serum
was removed and stored at 80°C until analysis. Serum car-
boxy-terminal collagen cross-links and osteocalcin were mea-
suredaccording to themanufacturer’s instructions (SBASciences
and Biomedical Technologies Inc). Myostatin was measured in
serumbyanELISAwithakit fromUnitedStatesBiologicalCorp)
following the manufacturer’s instructions.
Data analysis
We first tested the effects of exercise or loadingwithin groups
(PPAR/ and PPAR/) by paired or unpaired t tests. In the
mechanical loading experiments, we compared stimulated and
nonstimulated tibia in the same animal using a paired t test. For
the exercise investigation, we compared sedentary vs trained an-
imals using unpaired t tests. To compare the effect of genotype
and the response to loading (mechanical loading and exercise),
we used a two-way ANOVA. As appropriate, post hoc testing
was performed using Fisher’s protected least squares difference.
The P value of interaction between the genotype and loading
(mechanical stimulation or exercise) was mentioned only when
it was found to be significant. We then tested the effects of re-
peated measures within groups (for the effects of aging) by a
one-way repeated-measures ANOVAwith the genotype used as
a factor.Differenceswere considered significant atP .05.Data
are presented as mean  SEM.
Results
Body weight, lean mass, muscle strength, and
BMD
First, we confirmed that PPAR/mice were glucose
intolerant at 4 and 18 months and found that this alter-
ation was maintained, but not exacerbated, as they age
(Supplemental Figure 1A).We found the same trend at the
age of 12 months but the difference was not statistically
significant.
At 1 month of age, body weight and lean mass did not
significantly differ between PPAR/ and PPAR/
mice, indicating that PPAR deficiency did not affect em-
bryonic or early postnatal development. Between 1 and12
months of age, total and limb lean mass gains were lower
in PPAR/ vs PPAR/ (Figure 1, B and C), andmus-
cle strength declined in PPAR/, whereas it remained
stable for PPAR/ (Figure 1D). More specifically, gas-
trocnemius muscle mass became significantly lower with
age inPPAR/ vsPPAR/mice (4.6%at 4months
and 30.8% at 18 months of age, P  .05). Maximal
running distance was significantly reduced in old
PPAR/ vs PPAR/ mice, whereas the maximal
speedwas unchanged (Figure 1E).Moreover, quantitative
real-timePCRperformedonRNAfromthegastrocnemius
indicated lower Cyclin D1, Mip, Hif, Foxo3, mp2, and
BMP3 and higher Mstn expression in PPAR/ com-
pared with PPAR/ mice (Supplemental Figure 2).
IGF-1 expression was not significantly different between
PPAR/ and PPAR/ mice. BMD gain was unaf-
fected by PPAR deficiency until 4 months of age. How-
ever, by 12 months of age, total body and femur BMDs
were significantly lower in PPAR/ vs PPAR/ (Fig-
ure 1, F and G), paralleling the alterations in muscle
mass/function.
Bone microarchitecture, turnover, and
biomechanical properties
Age-related changes in trabecular microarchitecture
followed a similar pattern in the distal femur and caudal
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vertebrae, although in the femur the loss of BV/TV oc-
curred earlier and was more dramatic (Figure 2A). At the
vertebrae, the decline in BV/TV was higher in PPAR/
at 12 and 18 months of age (Figure 2B and Supplemental
Table 1), whereas trends were observed only at the distal
femur. In the same region, ie, the metaphysis of the distal
femur, old PPAR/ mice exhibit higher osmium stain-
ing, indicating more bone marrow adiposity (217% of
adipocyte volume per tissue volume vs PPAR/, P 
.05) (Figure 2C). In the midshaft femur, cortical tissue
volume and bone volume stabilized at the age of 12
months. At 18 months of age, PPAR/ mice exhibited
lower cortical tissue volume and bone volume compared
with PPAR/ mice (Figure 2, D and E) together with
increased endocortical porosity (Figure 2F). These
changes were associated with higher osteoclast number
and surface inPPAR/ vsPPAR/mice (Supplemen-
talTable1),whereas thebone-forming indiceswere lower,
particularly at the periosteal surfaces at a latter age (Figure
2, G–J). Consistent with bone histomorphometry, at 18
months of age, bone resorption (carboxy-terminal colla-
gen cross-links) andbone formation (osteocalcin)markers
were higher and lower, respectively, in PPAR/ than
PPAR/ mice (Supplemental Table 2), indicating that
bone turnover and coupling is altered in the absence of
PPAR. In addition, we found higher circulating levels of
myostatin in PPAR/ mice com-
pared with PPAR/ mice.
As evaluated by three-point bend-
ing, ultimate force and stiffness were
lower in PPAR/ mice compared
with PPAR/ mice at 4, 12, and
18months (Figure 2, K and L). At 18
months of age, the energy to fracture
was also significantly lower in
PPAR/comparedwithPPAR/
mice (Figure 2M).
Altered osteoblast
differentiation in PPAR-
deficient cells
To clarify the molecular mecha-
nisms by which PPAR deficiency
alters the bone forming activity, we
first examined bone mRNA expres-
sion levels in the old mice (18 mo of
age). Expression levels of genes as-
sociated with osteoblast and osteo-
cyte differentiation, as well as Foxo1
and Hmox, were significantly al-
tered inPPAR/mice (Figure3A).
Mstn as well as Fabp4 and Ppar
were also up-regulated in calvariae
from PPAR/ mice, ie, independent of weight-bearing
and muscle contraction, whereas Foxo1, Ctnnb (-
catenin), and Tnsf11b (Opg) gene expression was de-
creased (Figure 3B). Eventually, cultures of MSCs from
PPAR/ bone marrow showed a low expression levels
of Cbfa1 (38.3% and 41.0% vs PPAR/, respec-
tively, after 3 and 7 days of culture, P  .05) and an in-
creased propensity to differentiate into adipocytes (Figure
4A). An increased propensity to form mature adipocytes
was confirmed in primary osteoblast cultures from
PPAR/ calvariae under adipogenic conditions (Figure
4B) concomitant with lower osteoblast differentiation
(Figure 4C). Altogether these data indicate that PPAR
deficiency causes a cell-autonomous defect of the osteo-
blastic lineage.
Response to physical activity and loading
We first evaluated whether moderate physical activity
can restore the musculoskeletal phenotype of PPAR/
mice, particularly muscle force and bone formation at
periosteum surfaces.
Exercise increased body weight, limb lean mass, and
force in PPAR/ but not in PPAR/mice (Figure 5,
A–C). Exercise increased trabecular BV/TV in PPAR/
(124% vs sedentary, P  .05) and to a lesser extent in
Figure 1. Effect of aging in the absence of PPAR on body composition, muscle mass, and
strength. A, Body weight. B and C, Lean mass of the total body and limb evaluated by PIXImus
(GE Lunar). D, Mean force of the limb evaluated by handgrip. E, Maximal speed and distance
evaluated on a treadmill at 18 months of age. F and G, Total body and femur BMD. *, P  .05;
**, P  .01; ***, P  .001; ****, P  .0001 significant difference vs PPAR/ mice.
Continuous lines, PPAR/; hatched lines, PPAR/. Bars show means (SEM). Closed bars,
PPAR/; open bars, PPAR/.
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Figure 2. Effect of aging in the absence of PPAR on bone microarchitecture, bone formation indices, and strength. A, Trabecular BV/TV of
femur. B, BV/TV of the vertebral body. C, Upper panel, Illustration of three-dimensional trabecular structure of the distal femur in mice aged 18
months. Middle panel, Two-dimensional illustration of adipocytes stained at the distal femur by osmium and visualized by microcomputed
tomography. Lower panel, Three-dimensional reconstruction of adipocyte volume present in the marrow space. CtTV (D) and CtBV (E) at the
midshaft femur are shown. F, Two-dimensional reconstruction of the cortical midshaft illustrating the lower CtBV in part by increasing the
endocortical porosity. G–J, Bone formation indices at endocortical (Ec) and periosteal (Ps) surfaces. MAR, mineral apposition rate; MPm/BPm,
mineralization perimeter on bone perimeter. K–M, Biomechanical properties of the cortical femur obtained by three-point bending tests. *, P 
.05; **, P  .01; ***, P  .001 significant difference vs PPAR/ mice. Continuous lines, PPAR/; hatched lines, PPAR/ show means (
SEM).
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PPAR/mice (54%vs sedentary,P .05, Figure 5E).
However, exercise significantly increased femurBMDand
cortical structure (CtBV) in PPAR/ but not in
PPAR/ mice (Figure 5, D, F, and G). Moreover, ex-
ercise stimulated bone formation rate (BFR) at the endo-
cortical and periosteal surfaces in the PPAR/ but not
in the PPAR/ mice (Figure 5, H and I). These obser-
vations therefore indicate an altered muscle and bone an-
abolic response to exercise in the absence of PPAR. Of
note, exercise significantly reduced glucose area under the
curve in both PPAR/ and PPAR/ mice (Supple-
mental Figure 1B).
Having established that PPAR modulates the muscle
and bone response to moderate physical activity, we next
asked whether the lack of skeletal response in PPAR/
was secondary to the muscle dysfunction and/or could be
explained by an intrinsic failure of
the bone mechanotransduction. To
this aim, mice were subjected to di-
rect axial compression of the tibia in
vivo for 2 weeks. Contrasting with
exercise, axial compression of the
tibia significantly increased BMD
and CtBV in both PPAR/ and
PPAR/ mice (Figure 6, A–C).
Loading also stimulated periosteal
boneformationsimilarly inPPAR/
and PPAR/ mice (Figure 6, D
and F). However, at the endocortical
Figure 3. Effect of PPAR deficiency on gene expression relative to glyceraldehyde-3-phosphate dehydrogenase in the femur of mice aged 18
months (A) and in primary calvarial osteoblasts (B). Coll1a, collagen 1a; Bglap, osteocalcin; SP7, osterix; Sost, sclerostin; Mef2c, myocyte enhancer
factor 2b; Opg, osteoprotegerin; Foxo1, Forkhead box O1; Hmox, hemeoxygenase. *, P  .05; **, P  .01 significant difference vs PPAR/
mice. Bars show means ( sem). Closed bars, PPAR/; open bars, PPAR/.
Figure 4. Effect of PPAR deficiency on MSC differentiation into adipocytic lineage and primary
calvarial osteoblasts. A, Oil red O quantification after 14 days of MSCs prepared from PPAR/
and PPAR/ bone marrow culture in adipogenic medium. B, Oil red O quantification after 14
days of PPAR/ and PPAR/ calvaria culture in adipogenic medium and an illustration of the
presence of oil droplets in PPAR/ calvaria medium. C, Alkaline phosphatase (ALP) production
in osteoblasts from PPAR/ and PPAR/ mice calvariae after 14 days of culture. *, P  .05;
**, P  .01; ***, P  .001 by unpaired t test compared with PPAR/ mice.
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surface, loading increased the bone-forming indices only in
PPAR/ mice (Figure 6, E and F). Taken together, these
data indicate that PPAR deficiency alters the periosteal
modeling response induced by muscle activity but not by
direct mechanical loading, whereas alterations of endosteal
bone remodeling occur independently of muscle activity.
Discussion
Our results establish several important new findings re-
garding the role of PPAR in the pathogenesis of bone
fragility in diabetes. First, in the absence of PPAR, there
is an accelerated and parallel decline of muscle strength
Figure 5. Effect of treadmill exercise on body weight, muscle function, BMD, microarchitecture, and bone formation index in PPAR/ mice. A,
Body weight evaluated by PIXImus (GE Lunar). B, Lean limb mass evaluated by PIXImus. C, Muscle force evaluated by handgrip. D, Femur BMD. E,
Trabecular BV/TV. F, Illustration of three-dimensional trabecular structure of the distal femur. G, Cortical thickness (CtTh) at midshaft femur. H and
I, Bone formation rate on bone perimeter (BFR/BPm) at endocortical (Ec) and periosteal (Ps) surfaces. *, P  .05; **, P  .01 significant difference
vs sedentary group. Bars show means (SEM). Closed bars, exercise; open bars, sedentary.
Figure 6. Effect of axial compression on BMD, microarchitecture, and bone formation index in PPAR/ mice. A, Tibia BMD. B, Trabecular BV/TV
of the proximal tibia. C, CtBV at the midshaft tibia. D and E, Bone formation rate on bone perimeter (BFR/BPm) at endocortical (Ec) and periosteal
(Ps) surfaces. F, Fluorescent calcein labels on transverse cortical midshaft tibia. *, P  .05; **, P  .01; ****, P  .0001 significant difference vs
nonstimulated. Bars show means (SEM). Closed bars, stimulated tibia (S); open bars, nonstimulated tibia (Non-S).
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and bone formation, predominantly cortical, with age,
leading to lower mechanical properties (bone strength).
Interestingly, mechanical deterioration occurs before cor-
tical structure changes are observed, consistent with the
notion of early alterations in thematerial properties of the
bones in these mice. Second, exercise was not able to im-
prove muscle and bone parameters in PPAR/ mice,
whereas direct mechanical loading partially was success-
ful to this end by improving periosteal bone formation,
thereby suggesting that PPAR is involved in the reduced
ability of diabetic bone to withstand mechanical loading,
particularly at remodeling surfaces. Third, PPAR defi-
ciency led to increased PPAR expression in vivo and in
vitro, increased differentiation of MSCs into adipocytes,
and increased bone marrow adiposity, thereby providing
a new mechanism to explain the reduced bone formation
in relation to glucose intolerance and lipid accumulation.
The metabolic syndrome and T2DM are characterized
by a compromised ability of insulin to control glucose
disposal in muscle, increased hepatic glucose production,
andovert postprandial hyperglycemia. In accordancewith
the literature, our study confirms thatPPAR/mice are
metabolically less active and glucose intolerant from
young adulthood to older age (11). In our study the glu-
cose intolerance was not significant at 12 months of age,
but we still observed the same trend as at an earlier age.
This was probably due to an artifact of glucose measure-
ment or mice not completely fasted because PPAR/
mice are again intolerant at 18 months of age. We specif-
ically provide three lines of evidence indicating that
PPAR is also implicated in the pathogenesis of bone fra-
gility that could be observed in metabolic syndrome.
First, PPAR deficiency not only alters the proportion
of type II/type I fibers and muscle oxidative function (28)
but also plays a major role in the maintenance of muscle
mass and strength during aging. These two latter factors
are now recognized as significant determinants of bone
fragility and frailty (29, 30). Most prominently, PPAR
deficiency increasedmyostatin levels both locally and sys-
temically, which can negatively impact on both muscle
development andosteoblastic function (31–33). Indeed, in
vitro, PPAR activation induces myogenesis by inhibiting
myostatin expression (34). Interestingly, type 2 diabetic
patients have an up-regulated plasma myostatin associ-
ated with increased body mass index, higher fasting
plasma glucose, and blood insulin sensitivity (35, 36).
Myostatin and its receptors, type IIA and IIB activin Rc,
have become prominent targets for the development of
therapeutic inhibitors (37), with the potential for use in
muscle dysfunction associated with T2DM and sar-
copenic patients (now in phase II-III clinical trials, see
http://clinicaltrials.gov/ct2/results?termmyostatin&
SearchSearch). Thus, increased myostatin expression in
PPAR-deficient mice may at least partly explain their
poor muscle strength.
Second, in bone, PPAR has been shown to regulate
Opg expression and osteoclastogenesis through the
-catenin signaling pathway (20). We also observed de-
creased Ctnnb and Opg expression in PPAR-deficient
cells and an increase in osteoclast number and bone re-
sorption markers in PPAR/ mice. In accordance, we
observed theappearanceof cortical porosity inPPAR/
mice. Furthermore, our data demonstrate that PPAR in
bone cells plays a role in the regulation of osteoblast dif-
ferentiation and function with lower expression of Colla-
gen 1a, Runx2, and Osterix.
Wealsoshowanalterationofosteoblasticoxidativestress
in the absence of PPAR, as previously demonstrated in
myoblasts, endothelial cells, and theROS17/2.8osteoblastic
cell line (38–40). In vivo our results indicate that bone for-
mation indices are negatively altered at the endocortical sur-
faces at early time points and later on at the periosteum.
Consistent with this, PPAR/ exhibits a lower BMD and
cortical structure, ie, CtTV and CtBV in adult and oldmice.
With regard to the biomechanical properties, the femurs of
theknockoutmiceexhibit lowerultimate force, stiffness,and
energy to fracture. Interestingly, young adult PPAR/
miceexhibitadegradationofbiomechanicalpropertieswith-
out any significant changes in BMD and microarchitecture,
suggesting an alteration of bone material properties. Previ-
ous rodent models suggest that a dysregulation of glucose
metabolism leads toanaccumulationof reactiveoxygen spe-
ciessuchasadvancedglycationend-productsandsuperoxide
dismutase, which interact with bone matrix collagen and
therefore change themechanical properties of the bone (10).
This has been demonstrated in Zucker rats and yellow
KuoKondomice (41); however, all thesemodels exhibit
a low BMD. Therefore, PPAR/ mice are unique in
that they display similar key metabolic and skeletal
characteristics as in human T2DM patients, namely
lower mechanical properties and higher cortical poros-
ity in the absence of low BMD (5).
In addition PPAR/ mice were characterized by a
higher fat infiltration in the bone marrow, which can also
influence bone quality. This fat accumulation was asso-
ciated with an up-regulation of PPAR expression. In
vitro, we confirm a higher transdifferentiation activity of
PPAR/MSCs into adipocytes, paralleled by an over-
expression of PPAR. Activation of the PPAR2 isoform
leads toMSCdifferentiation toward the adipocyte lineage
at the expense of the osteoblast (42). Importantly, there
has been increasing evidence that the inverse correlation
between bone and fat phenotypes also exists in osteopo-
rosis (42) and T2DM patients (43).
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Third, exercise was unable to restore muscle and/or
bone mass and strength in PPAR/ mice, contrasting
with preclinical and clinical studies showing an improve-
ment ofmuscle function by exercise through an increase in
glycogen synthesis and a decrease in lipid accumulation in
rodent models of type 2 diabetes (44, 45) and T2DM sub-
jects (46, 47). In contrast, directmechanical loading of the
tibiae restored periosteal bone formation but not the en-
docortical response. We hypothesize that the lack of peri-
osteal bone response to exercise in PPAR/ may be
attributed to lower muscle contraction in these mice be-
cause muscle stimulation is not involved in the bone re-
sponse to direct mechanical loading. This explanation is
consistent with reports in the literature describing lower
muscle function correlating with reduced PPAR expres-
sion (48, 49), with the lower grip strength observed in the
PPAR / mice and with the known effects of muscle
contraction on bone structure (50). Alternatively, the lack
of PPAR in muscle may have altered the expression of a
bone growth factor such as Igf-1, bone morphogenetic
protein (Bmp), and/or other myokines, known to be in-
volved in the musculoskeletal system in response to exer-
cise (51, 52). In our model, Igf-1 is not significantly af-
fected; however, Bmps and Mstn are expressed,
respectively, less and more in PPAR/ mice compared
with their wild-type littermates. Thus, further studies
aimed at investigating whether the use of a myostatin in-
hibitor or BMP treatment can restore the bone response to
exercise of PPAR/ mice are warranted.
To potentially explain the absence of bone formation at
the endocortical surfaces in loaded PPAR/ mice, two
majorhypothesesare suggested.First, theabsenceofPPAR
mayalter the structure of the bonematrix, particularly at the
endocortical surface, and therefore impair itsmechanotrans-
duction properties, as we previously reported for the perios-
teal surfaces in periostin-deficient mice (26). Second, bone
marrowstemcellsarecapableof sensingexogenousmechan-
ical signals and shift MSC differentiation toward osteoblas-
togenesis and away from adipogenesis (53, 14). These alter-
ations have been related to decreased Runx2 and increased
PPAR expression, respectively (19), two transcriptions fac-
torsmodulated by PPAR. Therefore, the absence of a bone
response to axial compression at the endocortical compart-
ment could be attributed to the default ofMSCs to differen-
tiate into the osteoblastic lineage.
In conclusion, the absence of PPAR leads to threemajor
systemic changes, namely glucose intolerance, decreased
muscle strength, and exercise capacity, together with low
bone formation and response to exercise. At the molecular
level, PPAR appears to regulatemyostatin andPPAR lev-
els in muscle and bone, thereby providing potential new
mechanisms to explain bone fragility related to metabolic
syndromesandpotentially identifyingnewmolecular targets
for the treatment of muscle and bone fragility in diabetes.
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